CytomX Therapeutics Inc
NASDAQ:CTMX

  • LAST PRICE
    1.0900
  • TODAY'S CHANGE (%)
    0.0900 (9.0000%)
  • Bid / Lots
    1.0700/ 5
  • Ask / Lots
    1.0900/ 2
  • Open / Previous Close
    1.1500 / 1.0000
  • Day Range
    1.0600
    1.1600
  • 52 Week Range
    0.9801
    5.8500
  • Volume
    2,912,259

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 7, 2024

      Show headlines and story abstract

    • 4:39PM ET on Thursday Nov 07, 2024 by MT Newswires
      Companies Mentioned: CTMX
      04:39 PM EST, 11/07/2024 (MT Newswires) -- ...

    • 4:10PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: CTMX

      future results; the possibility that CytomX's clinical trials will not be successful; the possibility that current preclinical research may not result in additional product candidates; CytomX's dependence on the success of CX-904, CX-801, and CX-2051; CytomX's reliance on third parties for the manufacture of the Company's product candidates; possible regulatory developments in the United States and foreign countries; and the risk that we may incur higher costs than expected for research and development or unexpected costs and expenses. Additional applicable risks and uncertainties include those relating to our preclinical research and development, clinical development, and other risks identified under the heading "Risk Factors" included in CytomX's Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.

    • 4:10PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: CTMX

      future results; the possibility that CytomX's clinical trials will not be successful; the possibility that current preclinical research may not result in additional product candidates; CytomX's dependence on the success of CX-904, CX-801, and CX-2051; CytomX's reliance on third parties for the manufacture of the Company's product candidates; possible regulatory developments in the United States and foreign countries; and the risk that we may incur higher costs than expected for research and development or unexpected costs and expenses. Additional applicable risks and uncertainties include those relating to our preclinical research and development, clinical development, and other risks identified under the heading "Risk Factors" included in CytomX's Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.

  • Oct 31, 2024

Peers Headlines